- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07633938
The Effect of Eyelid Support Plate Assisted Eyelid Massage on Meibomian Gland Dysfunction: a Randomized Controlled Trial
8 de junho de 2026 atualizado por: Zhongshan Ophthalmic Center, Sun Yat-sen University
This study aims to conduct a randomized controlled clinical trial to compare the efficacy of a new type of massage device - eyelid support plate and glass rod assisted eyelid massage in improving MGD related dry eye symptoms, and evaluate the comfort and efficiency of both treatments, providing evidence-based support for clinical work
Visão geral do estudo
Status
Ainda não está recrutando
Tipo de estudo
Intervencional
Inscrição (Estimado)
142
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Qi Fu
- Número de telefone: 86+66619334
- E-mail: fuqi@gzzoc.com
Locais de estudo
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Zhongshan Ophthalmology Center, Sun Yat sen University
-
Contato:
- Bishan Tian
- Número de telefone: 86+66619334
- E-mail: tianbishan@gzzoc.com
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
Aceita Voluntários Saudáveis
Não
Descrição
Inclusion Criteria:
- Voluntarily participate and sign an informed consent form;
- Age range: 18 to 60 years old;
- Meet the diagnostic criteria for dry eye in the International Society of Tears and Ocular Surface (TFOS) Dry Eye Symposium (DEWS) II ;
- 1/3 or more of the meibomian gland openings are blocked or the secretion characteristics of the meibomian gland are abnormal;
- The best corrected visual acuity for each eye is ≥ 0.5;
- Eye pressure (IOP) ≥ 5mmHg and ≤ 21mmHg per eye;
- Women with reproductive potential agree to use reliable contraceptive methods during the study period;
- Willing and able to complete all planned research visits and follow the guidance of the researchers.
Exclusion Criteria:
- Contact lens use: Having used contact lenses within 14 days prior to the screening visit, or refusing to commit to discontinuing contact lens use during the study period (within the next 2 months);
- Had undergone corneal refractive surgery (e.g., LASIK/SMILE), other corneal surgeries, cataract surgery, anti-glaucoma surgery, or fundoscopic surgery within 12 months prior to enrollment screening;
- Participation in other medical studies within 3 months prior to enrollment screening;
Presence of any of the following active ocular diseases at present or within 3 months prior to screening: I) Acute allergic conjunctivitis; II) Infection (by bacteria, viruses, fungi, etc.); III) Inflammation (e.g., keratitis, retinitis).
Meningitis, choroiditis, uveitis, scleritis, etc.;
- Eyelid abnormalities affecting eyelid function (such as ptosis, blepharospasm, entropion, ectropion, etc.);
- Extensive ocular surface scars or conditions that may compromise ocular surface integrity (e.g., Stevens-Johnson syndrome, history of chemical burns, persistent corneal epithelial defects, history of ocular trauma, etc.);
- Currently or previously diagnosed with glaucoma, or undergoing treatment with anti-glaucoma medications;
- Has used any of the following ocular medications within the past 1 month: immunosuppressants, nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, or perfluorohexyloctane;
- Has received any of the following non-pharmacological treatments for dry eye within the past month: meibomian gland massage, deep eyelid margin cleansing, intense pulsed light therapy, or thermal pulsation therapy;
- During pregnancy or lactation;
- Neurological or psychiatric disorders (moderate to severe anxiety, depression, and sleep disorders);
- Uncontrolled ocular or systemic diseases;
- History of epilepsy;
- The investigator determines that the subject is not suitable for participation in this study.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: glass rod group
Implement glass rod assisted eyelid massage for a total of 4 times
|
The participants of control group receive sodium hyaluronate eye drops 4 times a day for 8 weeks, and receive glass rod assisted eyelid massage based on the group standard of "Meibomian gland massage operation procedure" (T/GDPMAA003-2023) every 2 weeks, for a total of 4 times.
Follow up evaluations will be conducted at weeks 4 and 8
|
|
Experimental: eyelid support plate group
Implement eyelid support plate assisted eyelid massage for a total of 4 times.
|
The participants of experimental group receive sodium hyaluronate eye drops in both eyes four times a day for 8 weeks, and receive eyelid support plate assisted eyelid massage based on the group standard of Meibomian gland massage procedure (T/GDPMAA003-2023) every two weeks for a total of four times.
Follow up evaluations will be conducted at weeks 4 and 8.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Mean change from baseline in Ocular Surface Disease Index (OSDI) score at week 8
Prazo: Baseline, week 4, week 8
|
The OSDI is a 12-item patient-reported outcomes questionnaire, which to provide a rapid assessment of the range of ocular surface symptoms, including symptoms related to chronic dry eye, their severity, and their impact on the patient's ability to function.Each item is rated based on the frequency of symptoms in the past week: never (0 points) → sometimes (1 point) → half the time (2 points) → most of the time (3 points) → always (4 points),total score 0-100 points.The higher the score, the more obvious the dry eye symptoms.
|
Baseline, week 4, week 8
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in first non-invasive tear film break time
Prazo: Baseline, week 4, week 8
|
The time (in seconds) from the blink that evenly distributed the fluorescein to the appearance of the first tear breakup was recorded.
First non-invasive tear film rupture time (NIBUTf) was measured using an ocular surface analyzer (Keratography 5M, Oculus, Germany),
|
Baseline, week 4, week 8
|
|
proportion of Ocular Surface Disease Index (OSDI) scores showing a change ≥10 points from baseline at week 8
Prazo: Baseline, week 4, week 8
|
The OSDI is a 12-item patient-reported outcomes questionnaire, which to provide a rapid assessment of the range of ocular surface symptoms, including symptoms related to chronic dry eye, their severity, and their impact on the patient's ability to function.Each item is rated based on the frequency of symptoms in the past week: never (0 points) → sometimes (1 point) → half the time (2 points) → most of the time (3 points) → always (4 points),total score 0-100 points.The higher the score, the more obvious the dry eye symptoms.
|
Baseline, week 4, week 8
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Average operating time of eyelid massage (min)
Prazo: Baseline, week 2, week 4, week 6
|
Record the operating time of each eyelid massage treatment in two groups (after completing surface anesthesia, from the start of eyelid massage to the completion of squeezing the upper and lower eyelids of both eyes, each eyelid is squeezed twice), timed by the same timer, and after the timer is over, the operating time (min) is recorded after verification by two researchers.
|
Baseline, week 2, week 4, week 6
|
|
change in non-invasive lacrimal height measurement(NITMH)
Prazo: Baseline, week 4, week 8
|
Non-invasive lacrimal height measurement(NITMH)(mm) using an ocular surface analyzer (Keratography 5M, Oculus, Germany)
|
Baseline, week 4, week 8
|
|
Change in meibomian gland absence status
Prazo: Baseline, week 4, week 8
|
Measurement of meibomian gland deficiency using an ocular surface analyzer (Keratography 5M, Oculus, Germany).
Grading criteria for meibomian gland deficiency: 0 points (normal)=no meibomian gland deficiency, 1 point (mild)=meibomian gland deficiency ratio less than 1/3, 2 points (moderate)=meibomian gland deficiency ratio between 1/3 and 2/3, 3 points (severe)=meibomian gland deficiency ratio greater than 2/3.
Determine the extent and severity of meibomian gland deficiency, calculate the sum of upper and lower eyelid grading scores for each eye, with a total score range of 0-6 points.
|
Baseline, week 4, week 8
|
|
Change in lipid layer thickness (LLT)
Prazo: Baseline, week 4, week 8
|
Evaluation of lipid layer yhickness (LLT)(nm) using LipiView
|
Baseline, week 4, week 8
|
|
Change in partial blink frequency
Prazo: Baseline, week 4, week 8
|
Evaluation of partial blink frequency (%) using LipiView.
|
Baseline, week 4, week 8
|
|
Changes in Meibomian gland discharge ability score
Prazo: Baseline, week 4, week 8
|
Apply force to the eyeball within the range of 5 meibomian gland openings outside and in the center of the lower eyelid eyelash line, and observe the number of meibomian gland openings that can discharge meibomian gland secretions.
Grading criteria: 0 points (normal)=all 5 meibomian gland openings excrete secretions, 1 point (mild)=3 or 4 meibomian gland openings excrete secretions, 2 points (moderate)=1 or 2 meibomian gland openings excrete secretions, 3 points (severe)=no meibomian gland openings excrete secretions,The higher the score, the worse the discharge ability.
|
Baseline, week 4, week 8
|
|
Change in score of meibomian gland secretions
Prazo: Baseline, week 4, week 8
|
Scoring by operator based on secretion characteristics.
Grading criteria:0 points (normal)=clear and transparent liquid secretion,1 point (mild)=cloudy liquid secretion,2 points (moderate)=cloudy granular secretion,3 points (severe)=thick and toothpaste like secretion.The higher the score, the worse the quality of the secretion
|
Baseline, week 4, week 8
|
|
comfort scores for four sessions of eyelid massage in two groups
Prazo: Baseline, week 2, week 4, week 6
|
Use the Visual Analog Scale (VAS) to score the comfort of the operation.The scale is mainly composed of a 100mm straight line, with one end representing "completely painless" and the other end representing "the most severe pain imaginable" or "extreme pain".
The score range is from 0 to 100, where 0 represents complete painlessness and 100 represents the most severe pain experienced by the patient.
Patients will be asked to mark the corresponding position on this line (using an "X") to represent the intensity of pain they experienced at that time.
Within 1 minute after each operation, have participants mark the corresponding position on the scale to indicate the intensity of their pain at that time, and promptly record each result.
|
Baseline, week 2, week 4, week 6
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Estimado)
1 de julho de 2026
Conclusão Primária (Estimado)
1 de julho de 2027
Conclusão do estudo (Estimado)
1 de setembro de 2027
Datas de inscrição no estudo
Enviado pela primeira vez
2 de junho de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
2 de junho de 2026
Primeira postagem (Real)
8 de junho de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
11 de junho de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
8 de junho de 2026
Última verificação
1 de maio de 2026
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2026KYPJ065
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
SIM
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .